Read by QxMD icon Read

Thrombosis and Haemostasis

Tze-Fan Chao, Gregory Y H Lip, Yenn-Jiang Lin, Shih-Lin Chang, Li-Wei Lo, Yu-Feng Hu, Ta-Chuan Tuan, Jo-Nan Liao, Fa-Po Chung, Tzeng-Ji Chen, Shih-Ann Chen
AIM:  When assessing bleeding risk in patients with atrial fibrillation (AF), risk stratification is often based on the baseline risks. We aimed to investigate changes in bleeding risk factors and alterations in the HAS-BLED score in AF patients. We hypothesized that a follow-up HAS-BLED score and the 'delta HAS-BLED score' (reflecting the change in score between baseline and follow-up) would be more predictive of major bleeding, when compared with baseline HAS-BLED score. METHODS AND RESULTS:  A total of 19,566 AF patients receiving warfarin and baseline HAS-BLED score ≤2 were studied...
March 6, 2018: Thrombosis and Haemostasis
Amelia Ruffatti, Marta Tonello, Ariela Hoxha, Savino Sciascia, Maria J Cuadrado, José O Latino, Sebastian Udry, Tatiana Reshetnyak, Nathalie Costedoat-Chalumeau, Nathalie Morel, Luca Marozio, Angela Tincani, Laura Andreoli, Ewa Haladyj, Pier L Meroni, Maria Gerosa, Jaume Alijotas-Reig, Sara Tenti, Karoline Mayer-Pickel, Michal J Simchen, Maria T Bertero, Sara De Carolis, Véronique Ramoni, Arsène Mekinian, Elvira Grandone, Aldo Maina, Fátima Serrano, Vittorio Pengo, Munther A Khamashta
The effect of additional treatments combined with conventional therapy on pregnancy outcomes was examined in high-risk primary antiphospholipid syndrome (PAPS) patients to identify the most effective treatment strategy. The study's inclusion criteria were (1) positivity to lupus anticoagulant alone or associated with anticardiolipin and/or anti-β2 glycoprotein I antibodies; (2) a history of severe maternal-foetal complications (Group I) or a history of one or more pregnancies refractory to conventional therapy leading to unexplained foetal deaths not associated with severe maternal-foetal complications (Group II)...
February 28, 2018: Thrombosis and Haemostasis
Anat Aharon, Anni Rebibo Sabbah, Liron Issman, Hila Berkovich, Reem Copty, Yeshayahu Talmon, Benjamin Brenner
BACKGROUND:  The involvement of extracellular vesicles (EVs) in cancer-associated thrombosis (CT) is unclear. This study aimed to explore the properties of EVs derived from breast cancer (BC) cells following exposure to high- or low-dose chemotherapeutic agents and evaluate thrombogenic effects of these EVs on endothelial cells (ECs). METHODS:  EVs were isolated from BC cell lines (non-metastatic MCF7, high-metastatic MDA-MB-231), pre-exposed to serum-free medium (control), with or without increasing doses of doxorubicin or paclitaxel...
February 28, 2018: Thrombosis and Haemostasis
L M Schütte, R M van Hest, S C M Stoof, F W G Leebeek, M H Cnossen, M J H A Kruip, R A A Mathôt
BACKGROUND: Nonsevere haemophilia A (HA) patients can be treated with desmopressin. Response of factor VIII activity (FVIII:C) differs between patients and is difficult to predict. OBJECTIVES: Our aims were to describe FVIII:C response after desmopressin and its reproducibility by population pharmacokinetic (PK) modelling. PATIENTS AND METHODS: Retrospective data of 128 nonsevere HA patients (age 7-75 years) receiving an intravenous or intranasal dose of desmopressin were used...
February 19, 2018: Thrombosis and Haemostasis
Øistein Rønneberg Mjelva, Gard F T Svingen, Eva K R Pedersen, Reinhard Seifert, Jan Terje Kvaløy, Øivind Midttun, Per M Ueland, Jan E Nordrehaug, Ottar Nygård, Dennis W T Nilsen
Systemic fibrinogen and neopterin are related to inflammation. We investigated the prognostic utility and possible interactions of these biomarkers in stable coronary artery disease (SCAD) patients undergoing coronary angiography. We included 3,545 patients with suspected stable angina with a median follow-up of 7.3 and 10.2 years for incident acute myocardial infarction (AMI) and all-cause mortality, respectively. Prospective associations were explored by Cox regression. Potential effect modifications were investigated according to strata of fibrinogen, neopterin or high-sensitivity troponin T (hsTnT) below and above the median, as well as gender and smoking habits...
February 19, 2018: Thrombosis and Haemostasis
Stella Thomassen, Tom G Mastenbroek, Frauke Swieringa, Kristien Winckers, Marion A H Feijge, Roy Schrijver, Judith M E M Cosemans, Susan A Maroney, Alan E Mast, Tilman M Hackeng, Johan W M Heemskerk
Tissue factor pathway inhibitor-alpha (TFPI-α) is a Kunitz-type serine protease inhibitor, which suppresses coagulation by inhibiting the tissue factor (TF)/factor VIIa complex as well as factor Xa. In static plasma-phospholipid systems, TFPI-α thus suppresses both factor Xa and thrombin generation. In this article, we used a microfluidics approach to investigate how TFPI-α regulates fibrin clot formation in platelet thrombi at low wall shear rate. We therefore hypothesized that the anticoagulant effect of TFPI-α in plasma is a function of the local procoagulant strength-defined as the magnitude of thrombin generation under flow, due to local activities of TF/factor VIIa and factor Xa...
February 16, 2018: Thrombosis and Haemostasis
Pamela L Lutsey, Keith J Horvath, Lisa Fullam, Stephan Moll, Mary R Rooney, Mary Cushman, Neil A Zakai
BACKGROUND: Warfarin and direct oral anticoagulants (DOACs) are used for the initial treatment and secondary prevention of venous thromboembolism (VTE), and have similar efficacy. Patient concerns and preferences are important considerations when selecting an anticoagulant, yet these are not well studied. METHODS: VTE patients ( n = 519) were surveyed from online sources (, and National Blood Clot Alliance Facebook followers [ n = 495]) and a haematology clinic in Vermont ( n = 24)...
February 15, 2018: Thrombosis and Haemostasis
Laura Martos, Luis Andrés Ramón, Julia Oto, Álvaro Fernández-Pardo, Santiago Bonanad, Ana Rosa Cid, Andras Gruber, John H Griffin, Francisco España, Silvia Navarro, Pilar Medina
BACKGROUND: Activated protein C (APC) is a major regulator of thrombin formation. Two major plasma inhibitors form complexes with APC, protein C inhibitor (PCI) and α 1 -antitrypsin (α 1 AT), and these complexes have been quantified by specific enzyme-linked immunosorbent assays (ELISAs). Also, complexes of APC with α 2 -macroglobulin (α 2 M) have been observed by immunoblotting. Here, we report an ELISA for APC:α 2 M complexes in plasma. METHODS: Plasma samples were pre-treated with dithiothreitol and then with iodoacetamide...
February 15, 2018: Thrombosis and Haemostasis
Manuel Carcao, Carmen Altisent, Giancarlo Castaman, Katsuyuki Fukutake, Bryce A Kerlin, Craig Kessler, Riitta Lassila, Diane Nugent, Johannes Oldenburg, May-Lill Garly, Anders Rosholm, Aida Inbal
Recombinant factor XIII-A 2 (rFXIII-A 2 ) was developed for prophylaxis and treatment of bleeds in patients with congenital FXIII A-subunit deficiency. mentor™2 (NCT00978380), a multinational, open-label, single-arm, multiple-dosing extension to the pivotal mentor™1 trial, assessed long-term safety and efficacy of rFXIII-A 2 prophylaxis in eligible patients (patients with severe [<0.05 IU/mL] congenital FXIII subunit A deficiency) aged ≥6 years. Patients received 35 IU/kg rFXIII-A 2 (exact dosing) every 28 ± 2 days for ≥52 weeks...
February 15, 2018: Thrombosis and Haemostasis
Mohamed Farag, Nikolaos Spinthakis, Manivannan Srinivasan, Keith Sullivan, David Wellsted, Diana A Gorog
The emergency management of ST-elevation myocardial infarction (STEMI) involves treatment with dual-antiplatelet therapy (DAPT) and primary percutaneous coronary intervention (PPCI). Pain is generally treated with opiates, which may delay gastric transit and reduce DAPT absorption. We sought to assess the effect of morphine on reperfusion, infarct size and thrombotic status in 300 patients presenting for PPCI. Morphine was given in a non-randomized fashion as required by emergency teams en route to the heart attack centre...
February 14, 2018: Thrombosis and Haemostasis
Loris Poli, Mario Grassi, Marialuisa Zedde, Simona Marcheselli, Giorgio Silvestrelli, Maria Sessa, Andrea Zini, Maurizio Paciaroni, Cristiano Azzini, Massimo Gamba, Antonella Toriello, Rossana Tassi, Elisa Giorli, Rocco Salvatore Calabrò, Marco Ritelli, Alessandro De Vito, Nicola Pugliese, Giuseppe Martini, Alessia Lanari, Corrado Lodigiani, Marina Padroni, Valeria De Giuli, Filomena Caria, Andrea Morotti, Paolo Costa, Davide Strambo, Manuel Corato, Rosario Pascarella, Massimo Del Sette, Giovanni Malferrari, Marina Colombi, Alessandro Padovani, Alessandro Pezzini
Whether to resume antithrombotic treatment after oral anticoagulant-related intracerebral haemorrhage (OAC-ICH) is debatable. In this study, we aimed at investigating long-term outcome associated with OAC resumption after warfarin-related ICH, in comparison with secondary prevention strategies with platelet inhibitors or antithrombotic discontinuation. Participants were patients who sustained an incident ICH during warfarin treatment (2002-2014) included in the Multicenter Study on Cerebral Hemorrhage in Italy...
February 12, 2018: Thrombosis and Haemostasis
Elena Furio, Maria Jose García-Fuster, Josep Redon, Patrice Marques, Rebeca Ortega, Maria Jesus Sanz, Laura Piqueras
Mechanisms linking deep vein thrombosis (DVT) and subclinical atherosclerosis and risk of cardiovascular events are poorly understood. The aim of this study was to investigate the potential impact of CX3 CR1/CX3 CL1 axis in DVT-associated endothelial dysfunction. The study included 22 patients (age: 37.5 ± 8.2 years) with a history of idiopathic DVT and without known cardiovascular risk factors and 23 aged-matched control subjects (age: 34 ± 7.8 years). Flow cytometry was used to evaluate peripheral markers of platelet activation, leukocyte immunophenotypes and CX3 CR1/CX3 CL1 expression in both groups...
February 12, 2018: Thrombosis and Haemostasis
Mar Martín-Pérez, David Gaist, Francisco J de Abajo, Luis A García Rodríguez
OBJECTIVE:  To investigate the population impact of previously reported interactions between warfarin and other drugs on international normalized ratio (INR) levels. METHODS:  Using The Health Improvement Network (THIN), a United Kingdom primary care database, a cohort of warfarin users between 2005 and 2013 (N = 121,962) was followed until the first qualifying prescription for the potential interacting drugs was evaluated. Sixteen sub-cohorts, one for each study drug, and a control sub-cohort of warfarin were ascertained...
February 12, 2018: Thrombosis and Haemostasis
Robert C Gosselin, Dorothy M Adcock, Shannon M Bates, Jonathan Douxfils, Emmanuel J Favaloro, Isabelle Gouin-Thibault, Cecilia Guillermo, Yohko Kawai, Edelgard Lindhoff-Last, Steve Kitchen
This guidance document was prepared on behalf of the International Council for Standardization in Haematology (ICSH) for providing haemostasis-related guidance documents for clinical laboratories. This inaugural coagulation ICSH document was developed by an ad hoc committee, comprised of international clinical and laboratory direct acting oral anticoagulant (DOAC) experts. The committee developed consensus recommendations for laboratory measurement of DOACs (dabigatran, rivaroxaban, apixaban and edoxaban), which would be germane for laboratories assessing DOAC anticoagulation...
February 12, 2018: Thrombosis and Haemostasis
Lan-Sun Chen, Ioannis Kourtzelis, Rashim Pal Singh, Sylvia Grossklaus, Ben Wielockx, George Hajishengallis, Triantafyllos Chavakis, Ioannis Mitroulis
No abstract text is available yet for this article.
February 7, 2018: Thrombosis and Haemostasis
L M van der Pol, T van der Hulle, A T A Mairuhu, M V Huisman, F A Klok
BACKGROUND:  Both the YEARS algorithm and the pulmonary embolism (PE) rule-out criteria (PERC) were created to exclude PE with limited diagnostic tests. A diagnostic strategy combining both scores might save additional computed tomography pulmonary angiography (CTPA) scans, but they have never been evaluated in conjunction. AIM:  The aim of this study was to determine the safety and efficiency of combining YEARS and PERC in a single diagnostic strategy for suspected PE...
February 1, 2018: Thrombosis and Haemostasis
Stefan H Hohnloser, Edin Basic, Christopher Hohmann, Michael Nabauer
All pivotal trials have evaluated non-vitamin K oral antagonists (NOACs) against warfarin. However, in some regions of the world, phenprocoumon is the most widely used vitamin K antagonist (VKA). There is little evidence documenting effectiveness and safety of NOACs compared with phenprocoumon in atrial fibrillation (AF). A retrospective cohort study using a German claims database was conducted to assess effectiveness (stroke, systemic embolism [SE]) and safety (bleeding leading to hospitalization) during therapy with NOACs and phenprocoumon in 61,205 AF patients...
January 22, 2018: Thrombosis and Haemostasis
Albert Ariza-Solé, Carme Guerrero, Francesc Formiga, Jaime Aboal, Emad Abu-Assi, Francisco Marín, Héctor Bueno, Oriol Alegre, Ramón López-Palop, María T Vidán, Manuel Martínez-Sellés, Pablo Díez-Villanueva, Pau Vilardell, Alessandro Sionis, Miquel Vives-Borrás, Juan Sanchís, Jordi Bañeras, Agnès Rafecas, Cinta Llibre, Javier López, Violeta González-Salvado, Àngel Cequier
BACKGROUND:  Bleeding risk scores have shown a limited predictive ability in elderly patients with acute coronary syndromes (ACS). No study explored the role of a comprehensive geriatric assessment to predict in-hospital bleeding in this clinical setting. METHODS:  The prospective multicentre LONGEVO-SCA registry included 532 unselected patients with non-ST segment elevation ACS (NSTEACS) aged 80 years or older. Comorbidity (Charlson index), frailty (FRAIL scale), disability (Barthel index and Lawton-Brody index), cognitive status (Pfeiffer test) and nutritional risk (mini nutritional assessment-short form test) were assessed during hospitalization...
March 2018: Thrombosis and Haemostasis
Per Lehnert, Theis Lange, Christian Holdflod Møller, Peter Skov Olsen, Jørn Carlsen
This study reports the incidence, clinical profile and mortality for acute pulmonary embolism (PE) patients in the Danish population in four eras from 2004 to 2014. Patients admitted with first-time acute PE from 2004 through 2014 were identified from national patient registries classified according to the International Classification of Diseases, 10th edition, World Health Organization. A total of 30,275 patients from a population of 4,301,673 adult residents aged 18 years or older were diagnosed with first-time acute PE, corresponding to an incidence of 64 (95% confidence interval: 61-66) per 100,000 adult residents per year...
March 2018: Thrombosis and Haemostasis
M M Abelleyro, V D Marchione, L Elhelou, C P Radic, L C Rossetti, D Neme, C D De Brasi
No abstract text is available yet for this article.
March 2018: Thrombosis and Haemostasis
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"